Page Title
Clinical Trial Finder
Anti-Inflammatory Closed to Enrollment
Phase 2 study of GS-5745 in adults with CF (Gilead GS-US-404-1808)
This two-part study will look at the effectiveness of the anti-inflammatory drug GS-5745 in adults with CF. Part 1 will test the drug at a higher dose, and Part 2 will test the drug at two lower dose levels. This study is placebo controlled, meaning that some participants will receive the study drug and others will receive a placebo. Both parts of the study will also offer an optional open-label extension period. During the extension period, all participants will receive the study drug. Researchers will test the effectiveness of GS-5745 by measuring lung function. This study may require lung function tests and/or other measurements.
Eligibility
-
Age:
18 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
40 to 80%
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Study Design
-
Study Type: ?more info
Interventional -
Randomized Study: ?more info
Yes -
Placebo Controlled: ?more info
Yes -
Length of Participation:
24 weeks -
Number of Study Visits:
6
Additional Information
-
Phase: ?more info
Phase Two -
Study Sponsor: ?more info
Gilead -
Study Drugs:
Study Sites
-
Closed to Enrollment
Alaska
Providence Alaska Medical Center, Anchorage, AK 99508
-
Closed to Enrollment
Arizona
Tucson Cystic Fibrosis Center, Tucson, AZ 85724
-
Closed to Enrollment
California
Center for Cystic Fibrosis at Keck Medical Center of USC, Los Angeles, CA 90033
-
Closed to Enrollment
Florida
Central Florida Pulmonary Group, Orlando, FL 32803
-
Closed to Enrollment
Florida
University of Florida, Gainesville, FL 32610
-
Closed to Enrollment
Florida
University of Miami, Miami, FL 33136
-
Closed to Enrollment
Idaho
Saint Luke's Cystic Fibrosis Center of Idaho, Boise, ID 83702
-
Closed to Enrollment
Illinois
CF Center Chicago (Glenview, Il), Glenview, IL 60025
-
Closed to Enrollment
Massachusetts
Boston Children's Hospital, Boston, MA 02115
-
Closed to Enrollment
Michigan
University of Michigan, Michigan Medicine, Ann Arbor, MI 48109
-
Closed to Enrollment
Minnesota
The Minnesota Cystic Fibrosis Center, Minneapolis, MN 55455
-
Closed to Enrollment
Missouri
Washington University School of Medicine, St. Louis, MO 63110
-
Closed to Enrollment
Ohio
University of Cincinnati Medical Center, Cincinnati, OH 45267
-
Closed to Enrollment
Oklahoma
Dr. Santiago Reyes Private Practice (Oklahoma City, Oklahoma), Oklahoma City, OK 73112
-
Closed to Enrollment
Pennsylvania
University of Pennsylvania, Philadelphia, PA 19104
-
Closed to Enrollment
Pennsylvania
University of Pittsburgh Medical Center, Pittsburgh, PA 15224
-
Closed to Enrollment
South Carolina
Medical University of South Carolina, Charleston, SC 29425
-
Closed to Enrollment
Wisconsin
University of Wisconsin, Madison, WI 53792
-
Closed to Enrollment
Wisconsin
Froedtert & Medical College of Wisconsin, Milwaukee, WI 53226
Eligibility
-
Age:
18 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
40 to 80%
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More